Sign in

CIK 0001870404

  • Emerging growth company

CERO THERAPEUTICS HOLDINGS, INC.

Sign in to watch
Tickers
CERO CEROW
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
871088814
Phone
+1 650-407-2376
Business address
201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
Former names
CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.

Securities

  • CERO Common stock OTC
  • CEROW Common stock OTC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-01-07 LAPORTE KATHLEEN Director Grant or award · Stock Option (Right to Buy) +690,900 690,900
2025-05-30 LAPORTE KATHLEEN Director Grant or award · Stock Option (Right to Buy) +9,326 9,326
2025-03-04 LAPORTE KATHLEEN Director Grant or award · Stock Option (Right to Buy) +17,923 17,923
2025-02-24 LAPORTE KATHLEEN Director Grant or award · Stock Option (Right to Buy) +127,500 255,000
2024-12-02 LAPORTE KATHLEEN Director Grant or award · Stock Option (Right to Buy) +127,500 127,500
2024-09-25 LAPORTE KATHLEEN Director Exercise or conversion +965,997 965,997
2024-09-25 LAPORTE KATHLEEN Director Exercise or conversion · Series A Convertible Preferred Stock −50 $1,000.00 $50K 0
2024-03-25 LAPORTE KATHLEEN Director Grant or award · Stock Option (Right to Buy) +112,500 112,500
2024-02-14 LAPORTE KATHLEEN Director Grant or award · Series A Convertible Preferred Stock +50 $1,000.00 $50K 50
2024-02-14 LAPORTE KATHLEEN Director Other acquisition +5,828 5,828
2024-02-14 LAPORTE KATHLEEN Director Grant or award · Series A Convertible Preferred Stock +50 $1,000.00 $50K 50
2021-10-08 LAPORTE KATHLEEN Director Other acquisition · Class B Common Stock +17,500 17,500

Page 1 of 1 · 12 trades